Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01659151 · ClinicalTrials.gov registry record · Phase 2
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01659151 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 17 participants.
The verdict
NCT01659151, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to find out more about the effects of an investigational combination of medicines, which includes special immune cells (T-cells). A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood cell that protect the body from viral infections, help other cells fight bacterial and fungal infections, produce antibodies, fight cancers, and coordinate the activities of other cells in the immune system.
Interventions
- DRUG Vemurafenib
- DRUG High Dose Interleukin-2 (IL-2)
- PROCEDURE ACT with TIL Infusion
- DRUG Lymphodepletion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-08-03 |
| Est. Completion | 2025-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01659151
The ClinicalTrials.gov registry entry for NCT01659151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vemurafenib is the first listed.
NCT01659151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01659151 about?
NCT01659151 is a clinical study titled "Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma". The purpose of this study is to find out more about the effects of an investigational combination of medicines, which includes special immune cells (T-cells). A T-cell is a type of lymphocyte, or white blood cell. Lymphocytes are a kind of white blood cell that protect the body from viral infection...
What is the current status of trial NCT01659151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2012-08-03. Estimated completion is 2025-08-19.
What interventions are being tested in trial NCT01659151?
The interventions under investigation include: Vemurafenib (DRUG), High Dose Interleukin-2 (IL-2) (DRUG), ACT with TIL Infusion (PROCEDURE), Lymphodepletion (DRUG).
Who is sponsoring clinical trial NCT01659151?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.